XML 45 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1

Segments of Business and Geographic Areas (Tables)

3 Months Ended

Apr. 01, 2018

Segment Reporting [Abstract]

Sales By Segment Of Business

SALES BY SEGMENT OF BUSINESS

		Fiscal First Quarters Ended
(Dollars in Millions)		April 1, 2018				April 2, 2017			Percent Change
CONSUMER
Baby Care
U.S.		$	97			113			(14.2	)%
International		360				342			5.3
Worldwide		457				455			0.4
Beauty
U.S.		611				567			7.8
International		473				414			14.3
Worldwide		1,084				981			10.5
Oral Care
U.S.		157				156			0.6
International		222				206			7.8
Worldwide		379				362			4.7
OTC
U.S.		465				477			(2.5	)
International		607				536			13.2
Worldwide		1,072				1,013			5.8
Women's Health
U.S.		3				3			0.0
International		240				239			0.4
Worldwide		243				242			0.4
Wound Care/Other
U.S.		103				98			5.1
International		60				77			(22.1	)
Worldwide		163				175			(6.9	)
TOTAL CONSUMER
U.S.		1,436				1,414			1.6
International		1,962				1,814			8.2
Worldwide		3,398				3,228			5.3
PHARMACEUTICAL
Immunology
U.S.		2,000				2,123			(5.8	)
International		1,042				807			29.1
Worldwide		3,042				2,930			3.8
REMICADE®
U.S.		916				1,182			(22.5	)
U.S. Exports		142				165			(13.9	)
International		331				325			1.8
Worldwide		1,389				1,672			(16.9	)
SIMPONI / SIMPONI ARIA®

U.S.		224				229			(2.2	)
International		294				199			47.7
Worldwide		518				428			21.0
STELARA®
U.S.		652				547			19.2
International		409				276			48.2
Worldwide		1,061				823			28.9
OTHER IMMUNOLOGY
U.S.		66				—			*
International		8				7			14.3
Worldwide		74				7			*
Infectious Diseases
U.S.		333				326			2.1
International		497				423			17.5
Worldwide		830				749			10.8
EDURANT® / rilpivirine
U.S.		14				12			16.7
International		196				137			43.1
Worldwide		210				149			40.9
PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
U.S.		273				259			5.4
International		205				171			19.9
Worldwide		478				430			11.2
OTHER INFECTIOUS DISEASES
U.S.		46				55			(16.4	)
International		96				115			(16.5	)
Worldwide		142				170			(16.5	)
Neuroscience
U.S.		624				664			(6.0	)
International		935				833			12.2
Worldwide		1,559				1,497			4.1
CONCERTA® / Methylphenidate
U.S.		66				108			(38.9	)
International		107				101			5.9
Worldwide		173				209			(17.2	)
INVEGA SUSTENNA® / XEPLION® / TRINZA® / TREVICTA®
U.S.		400				372			7.5
International		296				232			27.6
Worldwide		696				604			15.2
RISPERDAL CONSTA®
U.S.		82				95			(13.7	)
International		114				112			1.8
Worldwide		196				207			(5.3	)
OTHER NEUROSCIENCE
U.S.		76				89			(14.6	)

International		418				388			7.7
Worldwide		494				477			3.6
Oncology
U.S.		933				664			40.5
International		1,378				930			48.2
Worldwide		2,311				1,594			45.0
DARZALEX®
U.S.		264				201			31.3
International		168				54			*
Worldwide		432				255			69.4
IMBRUVICA®
U.S.		227				190			19.5
International		360				219			64.4
Worldwide		587				409			43.5
VELCADE®
U.S.		—				—			—
International		313				280			11.8
Worldwide		313				280			11.8
ZYTIGA®
U.S.		407				233			74.7
International		438				290			51.0
Worldwide		845				523			61.6
OTHER ONCOLOGY
U.S.		35				40			(12.5	)
International		99				87			13.8
Worldwide		134				127			5.5
Pulmonary Hypertension
U.S.		361				—			*
International		224				—			*
Worldwide		585				—			*
OPSUMIT®
U.S.		149				—			*
International		122				—			*
Worldwide		271				—			*
TRACLEER®
U.S.		68				—			*
International		72				—			*
Worldwide		140				—			*
UPTRAVI®
U.S.		124				—			*
International		16				—			*
Worldwide		140				—			*
OTHER
U.S.		20				—			*
International		14				—			*
Worldwide		34				—			*

Cardiovascular / Metabolism / Other
U.S.		1,103				1,095			0.7
International		414				380			8.9
Worldwide		1,517				1,475			2.8
XARELTO®
U.S.		578				513			12.7
International		—				—			—
Worldwide		578				513			12.7
INVOKANA® / INVOKAMET®
U.S.		204				247			(17.4	)
International		44				37			18.9
Worldwide		248				284			(12.7	)
PROCRIT® / EPREX®
U.S.		189				169			11.8
International		87				78			11.5
Worldwide		276				247			11.7
OTHER
U.S.		132				166			(20.5	)
International		283				265			6.8
Worldwide		415				431			(3.7	)
TOTAL PHARMACEUTICAL
U.S.		5,354				4,872			9.9
International		4,490				3,373			33.1
Worldwide		9,844				8,245			19.4
MEDICAL DEVICES
Diabetes Care
U.S.		117				154			(24.0	)
International		222				245			(9.4	)
Worldwide		339				399			(15.0	)
Diagnostics
U.S.		—				—			—
International		—				1			*
Worldwide		—				1			*
Interventional Solutions
U.S.		304				279			9.0
International		336				270			24.4
Worldwide		640				549			16.6
Orthopaedics
U.S.		1,307				1,359			(3.8	)
International		943				916			2.9
Worldwide		2,250				2,275			(1.1	)
HIPS
U.S.		209				209			0.0
International		154				143			7.7
Worldwide		363				352			3.1

KNEES
U.S.		228				246			(7.3	)
International		159				152			4.6
Worldwide		387				398			(2.8	)
TRAUMA
U.S.		407				391			4.1
International		289				251			15.1
Worldwide		696				642			8.4
SPINE & OTHER
U.S.		463				513			(9.7	)
International		341				370			(7.8	)
Worldwide		804				883			(8.9	)
Surgery
U.S.		993				995			(0.2	)
International		1,430				1,276			12.1
Worldwide		2,423				2,271			6.7
ADVANCED
U.S.		393				392			0.3
International		573				485			18.1
Worldwide		966				877			10.1
GENERAL
U.S.		423				423			0.0
International		704				651			8.1
Worldwide		1,127				1,074			4.9
SPECIALTY
U.S.		177				180			(1.7	)
International		153				140			9.3
Worldwide		330				320			3.1
Vision Care
U.S.		440				305			44.3
International		675				493			36.9
Worldwide		1,115				798			39.7
CONTACT LENSES / OTHER
U.S.		309				256			20.7
International		498				427			16.6
Worldwide		807				683			18.2
SURGICAL
U.S.		131				49			*
International		177				66			*
Worldwide		308				115			*
TOTAL MEDICAL DEVICES
U.S.		3,161				3,092			2.2
International		3,606				3,201			12.7
Worldwide		6,767				6,293			7.5
WORLDWIDE
U.S.		9,951				9,378			6.1

International		10,058				8,388			19.9
Worldwide		$	20,009			17,766			12.6	%

*Percentage greater than 100% or not meaningful

Operating Profit by Segment of Business

EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT

		Fiscal First Quarters Ended
(Dollars in Millions)		April 1, 2018				April 2, 2017			Percent Change
Consumer (1)		$	548			596			(8.1	)%
Pharmaceutical(2)		3,666				3,663			0.1
Medical Devices(3)		1,579				1,563			1.0
Segment earnings before provision for taxes		5,793				5,822			(0.5	)
Less: Expense not allocated to segments (4)		312				247
Worldwide income before tax		$	5,481			5,575			(1.7	)%

⁽¹⁾ Includes amortization expense of $0.1 billion in the fiscal first quarters of 2018 and 2017.

⁽²⁾ Includes acquisition costs related to the Actelion acquisition of $0.1 billion in the fiscal first quarter of 2018. Includes a gain of $0.2 billion in the fiscal first quarter of 2017 related to the sale of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. Includes amortization expense of $0.8 billion and $0.1 billion in the fiscal first quarters of 2018 and 2017, respectively.

⁽³⁾ Includes a restructuring related charge of $0.1 billion and $0.2 billion in the fiscal first quarters of 2018 and 2017, respectively. Includes amortization expense of $0.3 billion and $0.2 billion in the fiscal first quarters of 2018 and 2017, respectively.

⁽⁴⁾ Amounts not allocated to segments include interest income/expense and general corporate income/expense.

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas

SALES BY GEOGRAPHIC AREA

		Fiscal First Quarters Ended
(Dollars in Millions)		April 1, 2018				April 2, 2017			Percent Change
United States		$	9,951			9,378			6.1	%
Europe		4,797				3,858			24.3
Western Hemisphere, excluding U.S.		1,567				1,454			7.8
Asia-Pacific, Africa		3,694				3,076			20.1
Total		$	20,009			17,766			12.6	%

X

- Definition

Sales by segment of business.

+ References

No definition available.

+ Details

Name:	jnj_SalesBySegmentOfBusinessTableTextBlock
Namespace Prefix:	jnj_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

+ Details

Name:	us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8813-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8736-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration